|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Analyses of matched diagnosis and relapse specimens from individuals with KDM6A mutations showed an outgrowth of the KDM6A mutated tumor population at relapse.
|
31201358 |
2020 |
|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
We exploit the loss of function mutations in KDM6A and SWI/SNF complex to make bladder cancer cells susceptible to EZH2-based epigenetic therapy that activates an immune response to drive tumor cell differentiation and death.
|
30692641 |
2019 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
In conclusion, KDM6A exhibited essential roles in human PDAC as a tumor suppressor and KDM6A deficiency could be a promising biomarker for unfavorable outcome in PDAC patients and a potential surrogate marker for response to HDAC inhibitors.
|
30556125 |
2019 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
We also demonstrate that KDM6A-deficient pancreatic cancer is selectively sensitive to BET inhibitors, which reversed squamous differentiation and restrained tumor growth in vivo, highlighting a therapeutic niche for patient tailored therapies.
|
29533787 |
2018 |
|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Furthermore, using the next-generation sequencing approach, we identified mutations in the tumour suppressor genes KDM6A and TP53.
|
28695659 |
2018 |
|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Mutations in FGFR3 and KDM6A are more common in NMIBC than in MIBC, whereas mutations in TP53 and KMT2D are more common in MIBC, suggesting the previously hypothesized 2 different pathways, with a subset of tumors progressing from NMIBC to MIBC.
|
29573965 |
2018 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Inhibition of the Histone H3K27 Demethylase UTX Enhances Tumor Cell Radiosensitivity.
|
29483212 |
2018 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Efnb1 is overexpressed in UTX KO tumors and can lead to such phenotypes.
|
30006524 |
2018 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
A gene co-expression network identified using TCGA prostate tumour RNA-sequencing identifies co-regulated cancer genes associated with 2-oxoglutarate (2-OG) and succinate metabolism, including TET2, lysine demethylase (KDM) KDM6A, BRCA1-associated BAP1, and citric acid cycle enzymes IDH1/2, SDHA/B, and FH.
|
27819678 |
2017 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2.
|
28228601 |
2017 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Therefore, UTX-MLL4 immunoreactivity could be a useful predictor of the response to conventional treatment with radiotherapy or chemotherapy among GBM patients whose tumors have a methylated MGMT promoter.
|
27367247 |
2017 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
KDM6A is a candidate tumor suppressor gene that encodes a histone H3 lysine 27 (H3K27) demethylase.
|
28698146 |
2017 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
More mutations in the histone lysine demethylase KDM6A were present in non-invasive tumors from females than males.
|
29136510 |
2017 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Furthermore, we demonstrate that UTX, previously described as a tumor suppressor in T-ALL, is in fact a pro-oncogenic cofactor essential for leukemia maintenance in TAL1-positive (but not TAL1-negative) T-ALL.
|
26944678 |
2016 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
We further characterized how the gene structures of the oncogene JAK1 and the tumor suppressors KDM6A and RB1 are affected by somatic SVs and discussed the potential functional implications of intergenic SVs.
|
26283183 |
2015 |
|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Recurrent mutations were identified in tumor suppressor genes TP53 (n = 4), SMAD4 (n = 2), and CYLD (n = 2); and chromatin remodeling genes KDM6A (n = 3), SETD2 (n = 2), MLL3 (n = 2), and MLL2 (n = 2).
|
25299233 |
2015 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
We examined the function of KDM6A, altered in 24% of tumors, and show depletion in human bladder cancer cells, enhanced in vitro proliferation, in vivo tumor growth, and cell migration.
|
25225064 |
2014 |
|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Cancer genome sequencing has revealed the genetic basis of H3K27me deregulation, including mutations of the components of the H3K27 methyltransferase complex PRC2 and accessory proteins, and deletions and inactivating mutations of the H3K27 demethylase UTX in a wide variety of neoplasms.
|
24987060 |
2014 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Notably, we also report mutations affecting the MLL2-binding partner KDM6A, in 4 % (7/175) of tumors.
|
23184418 |
2013 |
|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Differences in expression profiles were also found to exist between individual breast tumors and, in some cases, were significantly associated with conventional pathological parameters and prognostic indices: tumor grade (K (lysine) acetyltransferase 5 (KAT5), HDAC1, KDM4A, SUV39H1 and KDM6A)); TNM stage (SUV39H1, K (lysine) acetyltransferase 2B (KAT2B), lysine (K)-specific demethylase 1A (KDM1A), KDM4A, lysine (K)-specific demethylase 5C (KDM5C), K (lysine) acetyltransferase 8 (KAT8), HDAC5 and KAT5)); Nottingham Prognostic Index (KDM5C, myeloid/lymphoid or mixed-lineage leukemia (MLL), KAT8 and SET and MYND domain containing 3 (SMYD3)); receptor status (KAT5, SMYD3 and KDM1A); histological type (KAT5, KDM5C, KAT8, KDM4A and MLL); disease-free survival (SUV39H1, SMYD3, HDAC5, KDM6A, HDAC1, KDM1A, KDM4A, KAT8, KDM5C, KAT5 and MLL) and overall survival (KAT8).
|
22199269 |
2011 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The H3K27me3 demethylase UTX functions in development and tumor suppression with undefined mechanisms.
|
20123895 |
2010 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
In summary, these data suggest that dUTX is a suppressor of Notch- and Rbf-dependent tumors in Drosophila melanogaster and may provide a model for UTX-dependent tumorigenesis in humans.
|
20212086 |
2010 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
Here, we describe inactivating somatic mutations in the histone lysine demethylase gene UTX, pointing to histone H3 lysine methylation deregulation in multiple tumor types.
|
19330029 |
2009 |